Primary prevention using statins: To be or not to be

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2701-2706

  Breimer, Lars H ^a   Mikhailidis, D P ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ApoB; Cascade screening; CVD; JUPITER; NNT; OTC statins; Primary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; PRIMARY PREVENTION; RISK REDUCTION;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NONPRESCRIPTION DRUGS; PATIENT SELECTION; PRIMARY PREVENTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77958142489     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.529887     Document Type: Editorial

References (53)

1. Ford I, et al. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86
2. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-7
3. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376; doi: 10.1136/bmj.b2376
5. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010;170:1024-31
6. Fereneczi EA, Asaria P, Hughes AD, et al. Can a statin neutralize the cardiovascular risk of unhealthy dietary choices? Am J Cardiol 2010;106:587-92
7. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9
8. Skolbekken J-A. Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ 1998;316:1956-8
9. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
10. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med 2010;170:1073-7
11. De Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010;170:1032-6
12. Green LA. Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med 2010;170:1007-8
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360:7-22
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
15. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet 2006;368:1155-63
16. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
17. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
18. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
19. Tziomalos K, Kakafika AI, Athyros VG, et al. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des 2009;15:1054-62
20. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 2010;122:25-34
21. Mundy A. Medicare Eye Study Finds Untapped Savings. Wall Street Journal, 2010
22. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459
23. Breimer LH, Mikhailidis DP. Statins and primary prevention. Arch Intern Med [2010] in press
24. Anonymous. Simvastatin over the counter. Drug Ther Bull 2005;43:25-8
25. Law MR, et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
26. Jones PH, Davidson MH, Stein EA, et al. for the STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
27. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7
28. Hansford D, Cunningham S, John D, et al. Community pharmacists' views, attitudes and early experiences of over-the-counter simvastatin. Pharm World Sci 2007;29:380-5
29. Filion KB, Delaney AC, Brophy JM, et al. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiol Drug Saf 2007;16:1-4
30. Stewart D, Cunningham ITS, Hansford D, et al. General practitioners' views and experiences of over-the-counter simvastatin in Scotland. Br J Clin Pharmacol 2010;70:356-9. doi: 10.1111/1365-2125. 2010.03701
31. Hung YT, Yeung VTF. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. H K Med J 2000;6:423-4
32. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
33. Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007;53:428-31
34. Joy TR, Hegele RA. Statin-related myopathy. Ann Intern Med. 2009; 150:858-68
35. Sawin CT. Subclinical hypothyroidism in older persons. Clin Geriatr Med 1995;11:231-8
36. Sundbeck G. Eden S. Jagenburg R., et al. Thyroid dysfunction in 85-year-old men and women. Influence of non-thyroidal illness and drug treatment. Acta Endocrinol 1991;125:475-86
37. Parle JV, Franklin JA, Cross KW. Prevalence and follow-up of abnormal thy-rotropin concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991;34:77-83
38. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years: study in an urban US community. Arch Intern Med 1990;150: 785-7
39. Food and Drug Administration 17 Dec 2007. cited in "FDA no to OTC statin"-www.theheart.org/article/833601.do
40. Tinetti ME. Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 2008;358:2728-32
41. Curtiss FR, Fairman KA. Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon? J Manag Care Pharm 2010;16:417-23
42. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut Published on line 2010. doi:10.1136/gut.2009.190900
43. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
44. Umans-Eckenhausen MA, Defesche JC, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8
45. Van Maarle MC, Stouthard MEA, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 2003;40:e3-e9
46. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63
47. Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112:3375-83
48. McQueen MJ, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33
49. The Emerging Risk Factors Collaboration (ERFC), Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
50. Sniderman A, Solhpour A. Targeting targets for LDL-lowering therapy. Clin Chem 2009;55:391-3
51. Gazi IF, Boumpas DT, Mikhailidis DP, et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007;25:102-11
52. Gasparyan AY, Stavropoulos-Kalinoglou A, et al. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010;8:437-49
53. Tziomalos K, Athyros VG, Karagiannis A, et al. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin 2009;25:133-7